[Phenylephrine as an adjuvant in the treatment of glaucoma (author's transl)].
Due to the fact that pilocarpin, which is predominantly used as a local therapeutic in glaucoma, is not satisfactory in all cases and has certain well-known disadvantages such as miosis, ciliaryspasm etc., great hope was set on adrenaline. Besides tachyphylaxis, its sensitivity to light and oxygen, and the danger of angle block glaucoma in eyes with a narrow iridocorneal angle the therapy was limited. Combinations of both substances would theoretically reduce the rate of adverse reactions and at the same time increase the therapeutic effect; however again stability is often a problem. Pilocarpin was therefore combined in a galenic form with phenylephrine, which, as well as possessing an effect of long duration, also confers an improved stability on the eyedrops. The substances were combined in 6 different ratios and tested clinically. With one exception a significant reduction in i.o. pressure could still be shown 8 and 24 hours after a single application. It has been demonstrated that more patients can be sufficiently controlled using the combination than with pilocarpin alone, and that concomitantly the therapeutic safety appears to be better than with the previously well-known bivalent combination-substances.
D004338:Drug Combinations; D004355:Drug Stability; D004357:Drug Synergism; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010656:Phenylephrine / Q000008:administration & dosage / Q000627:therapeutic use*; D010862:Pilocarpine / Q000008:administration & dosage / Q000627:therapeutic use
D004338:Drug Combinations; D009883:Ophthalmic Solutions; D010862:Pilocarpine; D010656:Phenylephrine
Phenylephrin als Adjuvans in der Glaukomtherapie